Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.
GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview.
Digital breast tomosythesis now makes up close to 50% of mammography systems in the U.S. "Tomo is going to replace just straight digital mammography simply because of the benefit of fewer recalls," explained Debra L. Monticciolo, MD.
The radiation doses associated with CT have decreased significantly, leaving nuclear cardiology as the modality with the highest doses in all of cardiac imaging. Rob deKemp, PhD, talked to us about some of the many ways imagers can work to address this issue.
Bhvita Jani, medical imaging principal analyst at Signify Research, discusses the evolution of theragnostics and its applications in nuclear imaging and oncology.
Bhvita Jani, medical imaging principal analyst at Signify Research, discusses the most recent innovations in computed tomography with Radiology Business Digital Editor Dave Fornell.
The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.
GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview.
Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.
